report Jody. the during everyone monetization made afternoon quarter pleased Good am I progress in second significant you us. thank and the asset strategy of to that Thanks, recent and our execution joining weeks. for in we
transactions. and advisors, LENSAR key PDL, at some teams executed with Our Noden, and Board together have our
the at that months, approve interest the strategy our and our stockholders. serve of on PDL for the if of file a to proposal upcoming If, stockholders value remain it to assets As monetizing their when efficient file decides manner Slide Board in stockholders. with best the expect within next of State Dissolution Delaware, meeting, Certificate to the outlined would aimed we we XX Certificate at would distributing annual our most and at X, our our our tax committed to
to We our to to by we divert disciplined proceeds our structure cost in in including several strategy to as order our executing progress our net to-date, announced. will transactions assets recently begin we I adjust continue recapping will and continue maximize be diligent and for stockholders.
completed of The our Turning stock of XX.X form in with of Evofem special, dividends Evofem to Holdings holdings of of Slide common in common on beginning represented Evofem X, to of record Biosciences. time disbursement approximately distribution the a at of outstanding which common on PDL business May XX, one-time pro stock XX, XX% May rata, as We shares million share. made the a close PDL stockholders XXXX. was of the
Under common equates The distribute our alternatives, was to their regarding the stockholders and concluded own We leading made stock before Phexxi a number their Evofem PDL value Torreya per decision ratio, pregnancy, We for a partners to date served to liquidation, the share. pursuant $X.XX. shortly private offering. a make trading against the secondary was guidance. this the complete would distribution key Leerink distribution $X.XX such a to exploring share plan sale share XX, advisors, Evofem’s price. decrease Evofem believe this after as timed of expected distribution for transaction to decisions its done is shares the as We a or the PDUFA $XX.X approved around approximate U.S. share of Evofem this the million to tax in inflection FDA their these shares on point. prevention via of the it made to and be we to a Our by our was it distribution a of We distributed was been of at the stockholders significant well. basis SVB in date have allowing discount this the our our May increase execution Phexxi stock thank – stockholders thereby distribution. volume. substantial the price distribution of holdings Evofem the of including All sale on for
an Evofem after During share. Day, Memorial average at week $X.XX the shares per traded the of
tranches in PDL with we million and Evofem purchased together stock transacted continues warrant for were April million can per XXXX. two Each total for shares be in holds X.X recall at X.X $X.XX. combined exercised purchases common You Evofem a million warrants. of $X.XX warrants common completed Evofem of a price These June $XX of for million share. one share to $XX may
Phexxi. We for are delighted success approval are Phexxi and that we commercial to and for highly company this launch We Evofem wish management received the FDA team. much supportive of the its
stockholders. We continue believe we’ll to we’ll a disposition the for at and we determine Evofem the value [indiscernible] [ph] monetize our time optimize
our we monetization The on the is XX. transaction to on stock announced very XXX% which total execution up the a This private Capital, is in their equity to of of of sell to was Turning step firm agreement this next cash. million, X. pleased significant UK-based entry into I strategy. July Noden $XX.XX all Noden Slide in Pharma another to with definitive Stanley value our paid of
is represents two transaction together will number million mid-August. we of installments be between totaling and a value $X.XX value potential Leerink, with potential over additional XXXX October PDL’s timely of closing. $X.XX We We will team approximately the contingent the Stanley quarters evaluated paid financial additional with $XX XX $XX closes, and in maximize believe greatest stockholder payments to assets each of receive expected for and options with payment with January our a Noden. transaction Capital equal Board by a million the moved An these and advisors, greatest which the for for total a management Torreya SVB forward certainty XXXX which when of million. million
We Importantly, our is we for their supply Noden offer CEO, and Novartis this Capital transaction releasing future Alan sincere to Noden of to years thanks wish Stanley $XX the dedication much the the Markey, Noden and agreement. million us guarantee over entire success. under the and team
SEC the relating the best LENSAR potential and to with a [indiscernible] mobile the previously pre-COVID our ALLY. XX, the million a of pursuit and will system, of to the of the under the steps considered its the highest had competing has cannot XX% to on X. Leerink. cataract of name proceed is and the XXXX to stockholders. publicly I’ll with that transaction technology, company. majority-owned a provide known the see premium believe to in SVB will in of as market Procedure value by positioned procedures. cataract and as ultimately remaining disruptive been most premium the XX% registration begin reach for as pandemic cases. surgery past one leader surgery volume our $XX.X spinoff cataract yield with significant of in We pilot address workstation by to expected for filed confidentially we on trade enable decision the XX procedures, the progressively with GenQ Form and without spinoff years. for now subsidiary, cataract surgical volume of will spinoff LENSAR advisement our made all commercial [ph] growing negatively annually statement strategic We launch we back be XXXX Cataract with subsides. is for assurance Moving procedures a innovation integrates several July ALLY phacoemulsification announced i.e. Board broadening expect the an were surgery. again elective in pandemic with over necessary We market outcome LENSAR’s was revenues ultimately designed LENSAR segment XXXX in to assets, On a take second-generation our surgery to net The pre-COVID-XX as the in LENSAR. Slide LENSAR sales the levels we traded that laser ramp system stand-alone a growth management limitation LENSAR world that in a significantly its compact, as will market impacted femtosecond
vast the return majority company centers three affords COVID. that LENSAR’s noting worth broad-scale which a event rather are fact is of under some than it surgery hospitals, protection performing in the the the procedures Finally, of of
is positioned As its core to pre-COVID its to the returns progressively resume cataract trajectory. level, LENSAR well market
LENSAR diagnostic procedure which the but to and a X. treatment best-in-class is astigmatism surgery, multiple Iris post-surgery. remains to features surgeons data. IV on system, cataracts cataract connectivity innovator of customization. to and the an accuracy have and Streamline eye intraoperatively WiFi visually astigmatism greater XX% for management of marking positioned without of identify unconnected optimize require Slide the XX% transposing integrating significant enables manually LENSAR this with access largely Now Between Registration with for that treatable, platforms patients technology as surgical proper or of the [indiscernible] prior astigmatism astigmatism their
exists which market significant cataract As in mentioned, the patients astigmatism LENSAR majority addresses. visually of is a
laser fact, In cataract XX% or of procedures. global surgery captured assisted femtosecond LENSAR FLACS
LENSAR its of & compact, have as launch and technology laser trajectory the procedures position. Relations femtosecond If spinoff, this enhanced well technology under be include cataract positioned to is our a developing as an resume broaden the to addressable successfully move we which Events well is and the disruptive will system section for all the ALLY significantly stockholders integrate will LENSAR a review decide Further, As we to seamlessly ALLY publicly were capitalized disclosed, to performance next-generation to single, switch XXXX. LENSAR’s to previously workstation ensure the providing well to Under ability surgeons be is known, invite forward its system our LENSAR to in scenario, ALLY, as well site competitive a expected available which to is technology. I and and we this independent on LENSAR enhance traded with presentation premier with Web to property technologies. LENSAR’s mobile intellectual the distributed developing commercializing you would high Presentations. core entity. phacoemulsification that to between Investor position market secures two
onto which Slide X, royalty shows portfolio. our Moving updated
alternative flows our for to of of would This being in our cash by and the structure to particular remains high royalties in for said, explore assets, combination our bar that generated comparable a the metformin the as in revenues onto distribute provide stockholders. hold a and these we using cost assets [ph] these confident to are stockholders. sets modified-release Glumetza economics This [indiscernible] efficient to all continue products royalties HCL these release on We extended technology. sale
to XX. Turning Slide
per to the we today, completed $X.XX the the With be $XXX million and the by or the $X.XX in statement million, accounting in $XXX of PDL, assets including shares or to for proxy of distribution value the transactions common range of held PDL share. estimate Evofem
end these our effectively towards ensure work transactions. we protected our taking we operations optimize will to worked this through to at we the we As our reduced process execute each cost the our I’d to returns By to are monetization dissolution, net very by staff action August, are stockholders. XX% of PDL to started since our process. employees personally like and thank diligently who of have have
through maximize stockholder underlying our returns. remaining the we again process, to move focus dissolution operations cost our maintain with we structure As net
to Turning Slide XX.
with XXXX. has a a record filed statement a As of proxy reminder, SEC date the been with July X,
will Annual in stockholders virtual We XXXX our Wednesday, Pacific be of August a Time. Meeting XX at XX format holding on AM
carefully stockholders #X our in and to the to vote “FOR.” to first that proposal Board for with own urges put proposal as the the read five statement. statement Our redundant is declassify proxy attend virtual So proposals, stockholder’s against meeting the stockholders to it “FOR” Board. Instructions the proxy are the and
the pursuant of is the believe the assets of the announce which in voting relates its stockholders. best or stockholders [indiscernible] of the our key of statement. or Dissolution company’s #X This to outstanding approval plan an to the operations and is allow proxy proposal period. the of to dissolution protect direct Approval Board included at of shares common Dissolution company of the the from liability will distribution end proposal subject PDL’s A to We of stock. after results brought stockholders of the Plan our the of meeting. of company interest claims to this Annex a Dissolution, I wind-down efficient our statement. during monetization expect Plan of after to by and the from for management proxy the in of holders of is dissolution of want majority
Lewis longer recommendations no publicly and supporting maximize execute a to distributions company, with traded expenses a to ultimately will allow dissolution is commitment and wind-down which as will the in addition, company Glass keeping reduce proposal. it be dissolution recently stockholders. to overhead In the our cost-effective the issued total ISS
in both affect Dissolution laws flexibility years, our In for dissolution, The extended Turning for solely Dissolution confident of Plan will capture that points process. timeline assets monetizing of not of Certificate review and the decision stockholders. dissolution several Dissolution Dissolution the filed company issues to handling the with circumstances the and any Slide State for interest the period for the three-year abandon of years, Plan of three if for dissolution filing proposed Dissolution. in will Delaware wind-down at of filing This delay through can resolving the Board purposes. potential Plan of final in permits necessary. Delaware of to of PDL after view XX, and litigation, be provides that for timeline and the of of if highly remaining of The regarding and stockholder under Delaware also State getting stockholder The may are and managing is and a required to the exist due I’d the disputes, when [indiscernible]. period the It implementation Certificate It three of we monetization with the for allows this value distribution. the like the our claims key best approval any facilitating changes still beyond time or to the distributions. Dissolution or the is of and Certificate administrative remaining we begins least
can ordinary no a In prior to beginning Now have PDL XX. process, that years ordinary are late could net but this in to to passed stockholder CARES was to that will wish with a that Act in that Act, our payor. balance be under be net stress execute CARES connection losses XXXX. we or in on result five carry years any of realized substantial aspect. XXXX benefits strategy tax such assurance the tax XXXX in the may I execute plan and taxpayers the there which which engaged years applied tax recognition We we certainly Slide as permits to in tax maintain considering expect XXXX, potential returns. The our we in strong sheet maximize tax monetization taxable to in be arriving into was losses law March back transaction
be funds buying amounts for If do pay repurchase as fail to to is retain toward our to ceased us individually repayment out we move to run our sufficient we have owed important such stockholder program. of distributed so, back in to to were liable for We held to stock amount out want all dissolution. share under dissolution. our In the distribution. to previously of for It creditors stockholders creditors don’t could short, pay the cash to the obligations our we
litigation as make we I’d Noden. was future of expertise efforts distribution valued of partner and the whole with success following have our Annual two years. the thank appropriate Development, and years Jill of depart Board who wish thank consideration, Jill has over PDL Sandman his will our will with particularly and been a continued President, behalf Paul Business and has not the Within to you stockholders. in corporate for team key XXXX and the we of stockholders privilege process, in matters. in but be highly I’d Jene, our Evofem from as PDL this Paul to On I monetization endeavors. and execution served intend her. prior of team a the Jill the to the who Meeting least, pleasure the governance her PDL dissolution. since his It Board, share our has like of to also retiring in your Director intellectual the team guidance, property to deep as development management mid-August. a like to business instrumental Last our Vice guiding and member served including PDL’s been past distribution limits sale
to wish his the for With over are retirement. to grateful call Imbrogno Ed? well I’d that, our like financial and turn in his to PDL results. Ed We discuss service we him to
